Enanta Pharmaceuticals (ENTA) earnings: investors are upbeat about the stock

9:58 pm ET, 23 Nov 2018

Enanta Pharmaceuticals, Inc. (ENTA) shares are trading at $78.99, roughly flat compared to previous close price. The company is announcing its quarterly earnings results on Monday after the market close. What's driving Enanta stock price? What's ENTA stock price forecast?

Enanta Pharmaceuticals is a biotechnology company, focused on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The stock has generated a return of 68% in the past year. The company announced a Phase 2a clinical trial evaluating orally administered EDP-938 against respiratory syncytial virus infection in a human challenge study.

Investors are showing interest in the company because of its strong product pipeline. On the other hand, few bearish investors feel that the stock is overvalued now. Last quarter’s revenue rose 392% to $44.05 million and earnings per share came at $0.97 compared to -$0.44 for the same period last year.

Fourth-quarter results will be released after market close on November 26, 2018.  Analysts expect the company to earn $1.17 per share on revenue of $68.52 million.  The company beat revenue estimate but missed EPS estimate by $0.01 in the previous quarter.

What is the sentiment towards the ENTA stock? Our technical analysis shows that:

  • The stock short-term sentiment (next 30 days) is trending positive;
  • The mid-term sentiment (3-6 months) is trending negative;
  • The long-term sentiment (9-12 months) is trending positive. 

Over the last month, Enanta Pharmaceuticals (ENTA) returned +1.16%.  Enanta Pharmaceuticals (ENTA) forward P/E ratio is 39.67, and it’s high compared to its industry peers’ P/E ratio.

Enanta Pharmaceuticals (ENTA) short share of float is 16.95%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock.

Enanta Pharmaceuticals (ENTA) average analyst price target ($100.67) is 23.98% above its current price ($81.20).

For the latest price and information on Enanta Pharmaceuticals, Inc., please visit Finstead and search for "ENTA price" or "ENTA news".

Enanta Pharmaceuticals, Inc. (ENTA) Stock Guide

Updated at: 7:14 pm ET, 17 Sep 2020

Before we start: if you're looking for ENTA stock price, you can quickly find it out by visiting Finny and typing "ENTA quote". If you're looking for a quick scoop on ENTA stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "ENTA". You'll get all this info in one place. Or you can just type "ENTA news" to get the latest stock news.

Looking to buy or sell Enanta Pharmaceuticals, Inc. (ENTA)? Interested in getting the full scoop on ENTA, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this ENTA stock guide, we'll address key questions about ENTA, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are ENTA earnings?
2. What is ENTA stock forecast (i.e., prediction)?
3. ENTA buy or sell? What is ENTA Finny Score?
4. What are the reasons to buy ENTA? Why should I buy ENTA stock?
5. What are the reasons to sell ENTA? Why should I sell ENTA stock?
6. What are ENTA key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are ENTA earnings?

ENTA trailing 12-month earnings per share (EPS) is $0.12.

Analyst Predictions

2. What is ENTA stock forecast (i.e., prediction)?

Based on ENTA analyst price targets, ENTA stock forecast is $67.57 (for a year from now). That means the average analyst price target for ENTA stock is $67.57. The prediction is based on 4 analyst estimates.

The low price target for ENTA is $45.00, while the high price target is $104.00.

ENTA analyst rating is Buy.

Analysis

3. ENTA buy or sell? What is ENTA Finny Score?

#{finnyScore:64}Our quantitative analysis shows 7 reasons to buy and 4 reasons to sell ENTA, resulting in Finny Score of 64.

4. What are the reasons to buy ENTA? Why should I buy ENTA stock?

Here are the reasons to buy ENTA stock:

5. What are the reasons to sell ENTA? Why should I sell ENTA stock?

Let's look at the reasons to sell ENTA stock (i.e., the bear case):

  • ENTA quarterly revenue growth was -58.00%, lower than the industry and sector average revenue growth (0.28% and 0.83%, respectively). See ENTA revenue growth chart.
  • ENTA profitability is declining. The YoY profit margin change was -7.32 percentage points. See ENTA profitability chart.
  • ENTA short share of float is 11.91%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See ENTA short share of float chart.
  • ENTA short interest (days to cover the shorts) ratio is 12.92. The stock garners more short interest than the average industry, sector or S&P 500 stock. See ENTA short interest ratio chart.

Key Stats

6. What are ENTA key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for ENTA:

Metrics ENTA
Price $43.75
Average Price Target / Upside $67.57 / 54.45%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 113
Market Cap $999.99M
Forward P/E Ratio -14.32
Price/Book Ratio 6.66
Revenue (TTM) $150.16M
YoY Quarterly Revenue Growth -58.00%
Profit Margin 1.57%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us